Literature DB >> 17385391

Contemporary management of peripheral arterial disease: III. Endovascular and surgical management.

Amjad Almahameed1, Deepak L Bhatt.   

Abstract

Traditional indications for invasive treatment in patients with peripheral arterial disease (PAD) have been salvage of a threatened limb or improvement of functional capacity in cases of disabling intermittent claudication, but advances in interventional therapy may be lowering the threshold for these therapies. Percutaneous transluminal angioplasty (PTA), with or without stent placement, is the most common endovascular intervention in patients with occlusive lower extremity PAD. In general, PTA is best suited to cases of short-segment stenosis or large-bore vessels, whereas surgery is best applied to multilevel occlusions involving smaller and more distant vessels. This article reviews endovascular therapy, catheter-based thrombolysis, and surgical revascularization procedures in patients with PAD, with special attention to recommendations from new American College of Cardiology/American Heart Association guidelines.

Entities:  

Mesh:

Year:  2006        PMID: 17385391     DOI: 10.3949/ccjm.73.suppl_4.s45

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  3 in total

1.  Long-term results of open and endovascular revascularization of superficial femoral artery occlusive disease.

Authors:  Salvatore T Scali; Eva M Rzucidlo; Aja A Bjerke; David H Stone; Daniel B Walsh; Philip P Goodney; Catherine K Chang; Richard J Powell
Journal:  J Vasc Surg       Date:  2011-05-28       Impact factor: 4.268

2.  Treatment of specific macrovascular beds in patients with diabetes mellitus.

Authors:  Allison M Petznick; Jay H Shubrook
Journal:  Osteopath Med Prim Care       Date:  2010-08-11

3.  Cost-effectiveness analysis of orbital atherectomy plus balloon angioplasty vs balloon angioplasty alone in subjects with calcified femoropopliteal lesions.

Authors:  Barry Weinstock; Raymond Dattilo; Tiffini Diage
Journal:  Clinicoecon Outcomes Res       Date:  2014-03-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.